Moderna on Oct. 22 said its vaccine for cytomegalovirus (CMV) did not perform well in a clinical trial.
The investigational shot did not meet the primary efficacy endpoint in preventing CMV infection in healthy females of childbearing age, or aged 16 to 40, Moderna said.
The phase 3 randomized, placebo-controlled trial involved about 7,500 women across approximately 300 sites in 13 countries, including Finland, Israel, and the United States.
The vaccine was developed to prevent CMV, which pregnant mothers can pass to their babies. About one in 200 babies in the United States is born with CMV, and about 20 percent of babies born with the virus have birth defects or long-term health problems such as hearing loss, according to the Centers for Disease Control and Prevention….